Hadrien Bouchez has extensive experience in the healthcare and biotechnology sectors, currently serving as a Partner at Kurma Partners since September 2014. Kurma Partners is a prominent European venture capital firm specializing in investments across various stages of company maturity, supported by a robust network of academic research partners. Hadrien Bouchez holds multiple board roles, including Board Director at Memo Therapeutics AG and Ermium Therapeutics, as well as Board Observer at Xeltis and Flamingo Therapeutics. Prior experience includes an Analyst position at Servier, focusing on drug acquisition and in-licensing, and a Research Scientist role at Université de Genève. Hadrien Bouchez's educational background includes degrees from HEC Paris, ESSEC Business School, University of Lille 1 Sciences and Technology, and University of Geneva.
This person is not in the org chart
This person is not in any teams